Fredric Jaffe
Pulmonary Disease · Philadelphia, PANPI 1043234008
Payments from drug & device makers
Across 57 payments — averaging $507.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$14K
- Boehringer Ingelheim$14K
- Harmony Biosciences LLC$196
- Insmed, Inc.$122
- Jazz Pharmaceuticals Inc.$98
- AstraZeneca$92
- plus $559 from 14 others
What the payments were for
- Food & beverage$1,324100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 9 | $14,153 |
| Boehringer Ingelheim | 4 | $13,714 |
| Harmony Biosciences LLC | 7 | $196 |
| Insmed, Inc. | 4 | $122 |
| Jazz Pharmaceuticals Inc. | 4 | $98 |
| AstraZeneca | 6 | $92 |
| Amgen | 4 | $82 |
| Mallinckrodt Hospital Products Inc. | 2 | $77 |
| Actelion Pharmaceuticals US, Inc. | 3 | $72 |
| Axsome Therapeutics, Inc. | 2 | $64 |
| Merck | 2 | $41 |
| Philips North America LLC | 2 | $35 |
| Baxter Healthcare | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Pulmonx Corporation | 1 | $22 |
| United Therapeutics Corporation | 1 | $22 |
| Resmed Corp | 1 | $19 |
| Mylan Specialty L.p. | 1 | $13 |
How this compares
$28,934 in reported general payments places this provider in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $25,298 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,500 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $14,153 | $32,79850 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$18.2M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Steven KelsenPhiladelphia$847K
- Parth RaliPhiladelphia$814K
- Kartik ShenoyPhiladelphia$701K
- Christopher ManleyPhiladelphia$580K
- Michaela AndersonPhiladelphia$515K
- Michael BaramPhiladelphia$501K
- Ross SummerPhiladelphia$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.